Collegium to Present at the 27th Annual Piper Jaffray Healthcare Conference
November 30, 2015 07:00 ET
|
Collegium Pharmaceutical
CANTON, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that Michael Heffernan, the Company's Chairman and CEO, will present at the 27th Annual...
Collegium Reports Third Quarter Financial Results and Provides Corporate Update
November 12, 2015 06:00 ET
|
Collegium Pharmaceutical
CANTON, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the third quarter of 2015 and provided a corporate...
Collegium to Host Conference Call to Discuss Q3 Financial Results and Provide Corporate Update
November 09, 2015 06:15 ET
|
Collegium Pharmaceutical
CANTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November...
Collegium Announces FDA Tentative Approval for Xtampza(TM) ER, a Novel Abuse-Deterrent Analgesic for Chronic Pain
November 09, 2015 06:00 ET
|
Collegium Pharmaceutical
CANTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the United States Food and Drug Administration (FDA) has granted tentative approval to...
Collegium Provides Update on FDA Review of Xtampza(TM) ER, an Abuse-Deterrent Analgesic for the Treatment of Chronic Pain
October 12, 2015 16:15 ET
|
Collegium Pharmaceutical
CANTON, Mass., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) has advised Collegium that it will not be...
Collegium Announces FDA Advisory Committees Unanimously Recommend Approval of Xtampza ER(TM), an Abuse-Deterrent Analgesic for Chronic Pain
September 11, 2015 21:18 ET
|
Collegium Pharmaceutical
CANTON, Mass., Sept. 11, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and...
Collegium to Present Highlights From Xtampza(TM) ER (Oxycodone Extended-Release Capsules) Clinical Development Program at PAINWeek
September 04, 2015 07:11 ET
|
Collegium Pharmaceutical
CANTON, Mass., Sept. 4, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data from the clinical development program for Xtampza™ ER, an...
Collegium Publishes Data From Xtampza(TM) ER Phase 3 Clinical Trial in the Journal PAIN
August 24, 2015 07:00 ET
|
Collegium Pharmaceutical
CANTON, Mass., Aug. 24, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from the Phase 3 clinical trial of Xtampza™ ER (oxycodone...
Collegium Reports Second Quarter Financial Results and Provides Corporate Update
August 12, 2015 17:00 ET
|
Collegium Pharmaceutical
CANTON, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the second quarter of 2015 and provided a corporate...
Collegium to Host Conference Call to Discuss Financial Results and Provide Corporate Update
August 07, 2015 09:00 ET
|
Collegium Pharmaceutical
CANTON, Mass., Aug. 7, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, August 13,...